ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0159

Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Abstract Number: 0160

Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Abstract Number: 0161

Validation of Patient-reported Outcomes (PRO) Lung Questionnaires for Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease
Abstract Number: 0162

Identifying Sleep Problems in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients with Patient-reported Outcomes (PRO) Questionnaires
Abstract Number: 0163

Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Abstract Number: 0164

What’s in a Name? Patient and Family Perspectives on the Naming of Systemic Juvenile Idiopathic Arthritis
Abstract Number: 0165

Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis
Abstract Number: 0166

Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Abstract Number: 0167

Rheumatoid Arthritis Patient Phenotypes from a Digital Health Coaching Engagement Program
Abstract Number: 0168

Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
Abstract Number: 0169

Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Abstract Number: 0170

Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 0171

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Abstract Number: 0172

Early Treatment and IL1RN Single Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 0173

mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].